Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
Haiying Zhang, Yuyuan Jia, Ying Ji, Xu Cong, Yan Liu, Ruifeng Yang, Xiangsha Kong, Yijun Shi, Ling Zhu, Zhenyu Wang, Wei Wang, Ran Fei, Feng Liu, Fengmin Lu, Hongsong Chen, Huiying Rao
doi: https://doi.org/10.1101/2021.08.18.21262214
Haiying Zhang
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Yuyuan Jia
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Ying Ji
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Xu Cong
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Yan Liu
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Ruifeng Yang
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Xiangsha Kong
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Yijun Shi
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Ling Zhu
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Zhenyu Wang
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Wei Wang
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Ran Fei
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Feng Liu
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Fengmin Lu
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Hongsong Chen
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Huiying Rao
Peking University People’s Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data used to draw the conclusions in this paper are provided in the paper and/or in the supplementary material.
Posted August 22, 2021.
Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
Haiying Zhang, Yuyuan Jia, Ying Ji, Xu Cong, Yan Liu, Ruifeng Yang, Xiangsha Kong, Yijun Shi, Ling Zhu, Zhenyu Wang, Wei Wang, Ran Fei, Feng Liu, Fengmin Lu, Hongsong Chen, Huiying Rao
medRxiv 2021.08.18.21262214; doi: https://doi.org/10.1101/2021.08.18.21262214
Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
Haiying Zhang, Yuyuan Jia, Ying Ji, Xu Cong, Yan Liu, Ruifeng Yang, Xiangsha Kong, Yijun Shi, Ling Zhu, Zhenyu Wang, Wei Wang, Ran Fei, Feng Liu, Fengmin Lu, Hongsong Chen, Huiying Rao
medRxiv 2021.08.18.21262214; doi: https://doi.org/10.1101/2021.08.18.21262214
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2599)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12134)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4028)
- Geriatric Medicine (379)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (831)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (563)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6469)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)